The U.S. FDA approved a molecularly targeted therapeutic to treat certain patients with cholangiocarcinoma. The U.S. Food and Drug Administration (FDA) approved the molecularly targeted therapeutic ivosidenib (Tibsovo) for certain patients with cholangiocarcinoma—bile duct...
The U.S. FDA granted accelerated approval to an immunotherapeutic and a companion diagnostic test to treat certain cancer patients whose tumors have a specific biomarker. The U.S. Food and Drug Administration (FDA) granted accelerated approval to...
The U.S. FDA approved a molecularly targeted therapeutic for certain patients with tumors associated with a raRe genetic disorder—von Hippel-Lindau disease. The U.S. Food and Drug Administration (FDA) approved belzutifan (Welireg), a targeted therapy for...
The U.S. FDA approved the combination of lenvatinib and pembrolizumab to treat adult patients with renal cell carcinoma, the most common form of kidney cancer. The U.S. Food and Drug Administration (FDA) approved the...
The U.S. FDA approved the immune checkpoint inhibitor pembrolizumab combined with chemotherapy to treat certain breast cancer patients before surgery. The U.S. Food and Drug Administration (FDA) approved the immunotherapeutic pembrolizumab for patients with...
The U.S. FDA approved a combination of a molecularly targeted therapeutic and an immunotherapeutic to treat certain patients with uterine cancer. The U.S. Food and Drug Administration (FDA) approved the combination of the immunotherapeutic...
The U.S. FDA approved a monoclonal antibody and enzyme combination for use in conjunction with chemotherapy and a steroid to treat patients with multiple myeloma. The U.S. Food and Drug Administration (FDA) approved...
The U.S. FDA approved an antibody-drug conjugate to treat urothelial cancer, the most common form of bladder cancer. The U.S. Food and Drug Administration (FDA) approved the molecularly targeted therapeutic enfortumab vedotin-ejfv (Padcev) to...
The U.S. FDA approved a new chemotherapy as part of a multi-drug regimen for certain patients with two similar blood cancers. The U.S. Food and Drug Administration (FDA) approved asparaginase erwinia chrysanthemi (recombinant)-rywn (Rylaze)...
The U.S. FDA has granted accelerated approval to the first KRAS inhibitor, along with two companion diagnostics, for certain patients with KRAS-mutated lung cancer. The U.S. Food and Drug Administration (FDA) granted accelerated approval...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More